Press & News

ViewReleaseInStandardHtml

Boule Diagnostics appoints a new Nomination Committee

Boule Diagnostics has appointed a new Nomination Committee for its 2016 Annual General Meeting. This committee represents approximately 35% of the number of shares and votes in the company, based on the share capital as at December 31, 2015.

This new Nomination Committee is tasked with submitting proposals to the Annual General Meeting for Board members, the Chairman of the Board, Board remuneration, any remuneration for committee work, the selection of and remuneration for the company’s auditors, and proposals for the principles for the composition of the Nomination Committee. The members of the Nomination Committee are:

  • Staffan Persson, Nortal Investment AB, Chairman of the Nomination Committee,

  • Ulf Hedlundh, Svolder AB,

  • Mats Andersson, Nordea Fonder, and

  • Peter von Ehrenheim, Chairman of Boule Diagnostics AB.

The proposals from the Nomination Committee will be presented in the invitation that will be published by 14 April at the latest for the 2016 Annual General Meeting and on the company website, www.boule.se. Nominations for Board members may be submitted to the Nomination Committee at www.boule.se/contact-us. Write “Nomination Committee” in the subject line. The 2016 Annual General Meeting of Boule Diagnostics will be held on Thursday, May 12 at 18.00 at the company’s premises in Spånga.

For more information, please contact:

Peter von Ehrenheim, Chairman of Boule Diagnostics AB, tel. +46(0)70-667 57 11

About Boule Diagnostics AB (publ)

Boule Diagnostics AB is a rapidly growing diagnostics company that develops, manufactures and markets systems and consumables for blood cell counts (hematology) to outpatient care. The company is primarily oriented to small and medium sized hospitals, clinics and laboratories within outpatient care, and to other diagnostics companies within both human and veterinary hematology. The company operates via subsidiary companies in Sweden, USA and China. Boule Diagnostics shares have been listed on the Nasdaq Stockholm Exchange since 2011. Additional information about Boule can be found at www.boule.se.

Boule Diagnostics AB is required to publish the information in this press release by the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information is embargoed for publication until 08:55 (CET) on January 26, 2016.